Benign Prostatic Hyperplasia (BPH)

Oncology·MeSH: Prostatic Hyperplasia

Prevalence

1564.6 / 100K

Incidence

190.6 / 100K/yr

3 drugs in development·3 companies·2 clinical trials

Drug Pipeline by Phase

Compare drugs

aquablation therapy vs tulsa-proaquablation therapy vs alpha blocker and 5-alpha reductase inhibitor

Frequently asked questions

How many drugs are in development for Benign Prostatic Hyperplasia (BPH)?

BioSniper tracks 3 drugs in development for Benign Prostatic Hyperplasia (BPH) across 3 companies.

How many clinical trials target Benign Prostatic Hyperplasia (BPH)?

There are 2 clinical trials targeting Benign Prostatic Hyperplasia (BPH) tracked by BioSniper.

What is the prevalence of Benign Prostatic Hyperplasia (BPH)?

The estimated prevalence of Benign Prostatic Hyperplasia (BPH) is approximately 1564.6 per 100,000 population.

Deep-dive into Benign Prostatic Hyperplasia (BPH)

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    Benign Prostatic Hyperplasia (BPH) — Drugs in Development & Clinical Trials | BioSniper